文献速递组学、生物样本库与精准医学流行病学与生物统计基础与转化研究

临床队列中的常见疾病——并非总是所见即所得

Common Diseases in Clinical Cohorts - Not Always What They Seem.
PubMed 文献 · N Engl J Med · 2025-01-01

研究利用英国生物银行及五项临床试验的外显子组和基因组测序数据,评估被诊断为多发性硬化、炎症性肠病或特应性皮炎患者中单基因罕见病的发生率,发现部分患者携带可致分子诊断的罕见变异,且分子诊断可解释治疗反应不佳的机制。

要点

  • 英国生物银行中多发性硬化患者53/1850(2.86%)携带罕见致病变异。
  • 炎症性肠病患者75/6681(1.12%)、特应性皮炎患者25/998(2.50%)携带罕见致病变异。
  • 在独立队列中重复了上述罕见致病变异的发现,分子诊断可揭示治疗反应不佳的机制。

核心结论

  • 系统基因组测序有助于理解常见疾病的表型异质性并识别未诊断的罕见病,深度分子表型分析对临床试验和患者诊疗有益。

研究设计与样本

  • 研究使用英国生物银行研究项目及五项临床试验参与者的外显子组和基因组测序数据,这些参与者分别被初步诊断为多发性硬化、炎症性肠病或特应性皮炎。

主要发现

  • 在英国生物银行中,鉴定出153名携带罕见变异并构成单基因疾病分子诊断的参与者:多发性硬化患者53/1850(2.86%)、炎症性肠病患者75/6681(1.12%)、特应性皮炎患者25/998(2.50%)。
  • 在两个独立队列中重复了上述罕见致病变异的发现,一个队列包括被诊断为多发性硬化的患者,另一个队列包括被诊断为炎症性肠病的患者,分别接受了用于研究和临床试验的基因组测序。
  • 通过结合基因组和转录组分析,表明分子诊断有可能阐明治疗干预反应不足的机制。

临床怎么用

  • 原文结论指出系统基因组测序有助于理解常见疾病的表型异质性并识别未诊断的罕见病,深度分子表型分析对临床试验和患者诊疗有益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Misdiagnosis or underdiagnosis of rare diseases in patients with diagnoses of common diseases can lead to delayed or inappropriate treatments, thereby complicating the management of both rare and common conditions. Despite advances in molecular diagnostic techniques, the effect of rare diseases on the diagnosis of common diseases in research and clinical trials has not been comprehensively investigated. METHODS: We used exome- and genome-sequencing data from participants in the U.K. Biobank, a research study, and five clinical trials involving patients who had received a primary diagnosis of multiple sclerosis, inflammatory bowel disease, or atopic dermatitis to assess the incidence of monogenic rare diseases that often manifest with clinical symptoms overlapping with those of these common diseases. RESULTS: We identified 153 U.K. Biobank participants who carried a rare variant that contributes to a molecular diagnosis of a monogenic disorder - 53 of 1850 (2.86%) with a diagnosis of multiple sclerosis, 75 of 6681 (1.12%) with a diagnosis of inflammatory bowel disease, and 25 of 998 (2.50%) with a diagnosis of atopic dermatitis. We replicated the findings regarding such rare disease-causing variants in two independent cohorts - one including patients with a diagnosis of multiple sclerosis, and the other patients with a diagnosis of inflammatory bowel disease - who had undergone genome sequencing for research and for clinical trials, respectively. By combining genome and transcriptome analyses, we showed that molecular diagnosis can potentially elucidate mechanisms of inadequate response to therapeutic intervention. CONCLUSIONS: Our study shows the value of systematic genome sequencing in understanding the phenotypic heterogeneity of common diseases and identifying failure to diagnose rare diseases and highlights the benefits of deep molecular phenotyping in clinical trials and patient care. (Funded by AbbVie and NIHR Cambridge Biomedical Research Centre.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Rahimov F, Jacobs BM, Lee JS, et al. Common Diseases in Clinical Cohorts - Not Always What They Seem. N Engl J Med. 2025. PMID: 41124632. doi:10.1056/NEJMoa2405459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。